Contraception
Volume 80, Issue 1 , Pages 44-52 , July 2009

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone

  • Monika Schöller-Gyüre

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 15 461 734; fax: +32 15 286 347.
    • ,
  • Thomas N. Kakuda

      Affiliations

    • Research and Development, Tibotec Inc., Yardley, PA 19067, USA
    • ,
  • Brian Woodfall

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium
    • ,
  • Fatima Aharchi

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium
    • ,
  • Monika Peeters

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium
    • ,
  • Kati Vandermeulen

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium
    • ,
  • Richard M.W. Hoetelmans

      Affiliations

    • Research and Development, Tibotec BVBA, B-2800 Mechelen, Belgium

Received 26 August 2008 ,Revised 21 November 2008 ,Accepted 21 January 2009.

References 

  1. UNAIDS annual AIDS epidemic update, 2007, Geneva, Switzerland. Accessed July 3, 2008 at: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf
  2. Massad LS, Evans CT, Wilson TE, Golub ET, Sanchez-Keeland L, Minkoff H. Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt). 2007;16:657–666
  3. Macqueen KM, Johnson L, Alleman P, Akumatey B, Lawoyin T, Nyiama T. Pregnancy prevention practices among women with multiple partners in an HIV prevention trial. J Acquir Immune Defic Syndr. 2007;46:32–38
  4. Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect. 2004;80:167–173
  5. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46:133–157
  6. Reed MJ, Fotherby F. Intestinal absorption of synthetic steroids. J Steroid Biochem. 1979;11:1107–1112
  7. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004;32:1209–1212
  8. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol. 2000;50:333–337
  9. Palovaara S, Tybring G, Laine K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003;56:232–237
  10. LeBel M, Masson E, Guilbert E, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol. 1998;38:1042–1050
  11. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680–4686
  12. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773–12782
  13. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38
  14. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48
  15. Trottier B, Johnson M, Katlama C, et al. Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. In: 17th Annual Canadian Conference on HIV/AIDS Research, April; Montreal, Canada. 2008;[Abstract P167]
  16. Kakuda TN, Schöller-Gyüre M, Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. In: 8th International Congress on Drug Therapy in HIV Infection, November; Glasgow, United Kingdom. 2006;[Abstract PL5.2]
  17. Schöller-Gyüre M, Kakuda TN, Van Solingen RM, et al. No clinically relevant effect of etravirine (ETR;TMC125) on digoxin pharmacokinetics in HIV-negative volunteers. In: 9th International Workshop on Clinical Pharmacology in HIV Therapy, April; New Orleans, LA, USA. 2008;[Abstract P22]
  18. Schöller-Gyüre M, Boffito M, Pozniak AL, et al. Effect of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 2008;28:1215–1222
  19. Sustiva Package Insert. Bristol-Myers Squibb Company; March 2008;Available at: http://packageinserts.bms.com/pi/pi_sustiva.pdf
  20. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep. 2007;4:135–140
  21. Intelence Prescribing Information. Tibotec, Inc.; January 2008;Available at: http://www.intelence-info.com/intelence/assets/pdf/INTELENCE_PI.pdf
  22. Viramune. Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc.; November 2008;Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf
  23. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance?. AIDS. 2008;22:989–990
  24. Ortho-Novum 1/35 (norethindrone and ethinyl estradiol) package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc.; September 2008;Available at: https://www.ortho-mcneilpharmaceutical.com/ortho-mcneilpharmaceutical/shared/pi/orthonov.pdf
  25. Regulatory Compliance Center. Division of AIDS table for grading severity of adult adverse experiences; August 1992. Accessed July 3, 2008 http://rcc.tech-res-intl.com/tox_tables.htm
  26. Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers. Br J Clin Pharmacol. 2008;66(4):508–516
  27. Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother. 2008;42:757–765
  28. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002;29:471–477
  29. Sevinsky H, Eley T, He B, et al. Effect of efavirenz on the pharmacokinetics of ethinyl estradiol and norgestimate in healthy female subjects. In: 48th Annual ICAAC/IDSA 46th Meeting October; Washington, DC, USA. 2008;[Abstract A-958]
  30. Hendrix CW, Jackson KA, Whitmore E, et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004;75:464–475
  31. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111–116
  32. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007;51:3617–3626
  33. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol. 2001;98:218–223
  34. Crixivan (indinavir sulfate) package insert. Merck&Co., Inc.; April 2006;Available at: http://www.crixivan.com/crixivan/shared/documents/pi.pdf
  35. Lipitor (atorvastatin calcium) package insert. Pfizer, Inc.; November 2007;Available at: http://www.pfizer.com/files/products/uspi_lipitor.pdf
  36. EMEA CPMP Public assessment report: combined oral contraceptives and venous thromboembolism. Doc.Ref:EMEA/CPMP/2201/01/en/Final 2001.
  37. Stanczyk FZ, Ploszaj S, Gentzschein E, Qian D, Mishell DR. Effect of oral contraceptives containing 20 and 35 micrograms ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers. Contraception. 1999;59:17–23
  38. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case–control study. Contraception. 2002;65:187–196
  39. Moutos D, Smith S, Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception. 1995;52:105–109
  40. Kakuda TN, Schöller-Gyüre M, Peeters M, et al. Pharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-infected patients. In: 9th International Workshop on Clinical Pharmacology in HIV Therapy April; New Orleans, LA. 2008;[Abstract P34]

☆ Disclosure: All authors are employees of Tibotec.

☆☆ Funding for this study was provided by Tibotec.

★ Presented in part at the 8th International Congress on Drug Therapy in HIV infection, Glasgow, United Kingdom, 12–16 November 2006, poster P277.

PII: S0010-7824(09)00026-2

doi: 10.1016/j.contraception.2009.01.009

Contraception
Volume 80, Issue 1 , Pages 44-52 , July 2009

Article Tools

* Image Usage & Resolution